ÂÜÀòÂÒÂ×

Matthew Figley is a Principal Scientist at Vigil Neuroscience, where Matthew discovers and develops novel therapeutics based on breakthroughs in basic science and human genetics of microglia. Prior to this role, Matthew was a Postdoctoral Research Scholar at Washington University in St. Louis, focusing on the molecular mechanisms of Wallerian axon degeneration. Matthew completed their Ph.D. in Neuroscience at Stanford University, where Matthew studied the genetics of Amyotrophic Lateral Sclerosis (ALS) in Aaron Gitler's lab. Matthew holds a Bachelor of Science degree in Neuroscience & History and Philosophy of Science from the University of Pittsburgh.